UPM Pharmaceuticals to Manufacture BioPharmX's Fir
Post# of 223
Posted On: 12/10/2014 5:00:41 PM
UPM Pharmaceuticals to Manufacture BioPharmX's First Commercially Available Product
BRISTOL, Tenn., Dec. 10, 2014 /PRNewswire/ -- UPM Pharmaceuticals, a division of Gregory Pharmaceutical Holdings, Inc., has reached an agreement with BioPharmX, Inc. (OTCQB: BPMX) to commercially manufacture solid dose iodine supplement tablets for the consumer products sector. The tablets will be manufactured at UPM's 475,000 square-foot manufacturing facility in Bristol, Tennessee, under a commercial supply agreement. Terms of the agreement were not disclosed.
Dr. John M. Gregory, Chairman and CEO of Gregory Pharmaceutical Holdings, Inc., said, "UPM's new large-scale manufacturing facility and capabilities for solid dose processing is an ideal setting for BioPharmX, which has a focus on patented products in fast growing markets."
Anja Krammer, President of BioPharmx, commented, "BioPharmX is impressed with UPM's customer focus and agile responsiveness toward supporting outsourced manufacturing needs, both critical elements to BioPharmX's anticipated growth in the over-the-counter and dietary supplements industry. We are excited about our planned product portfolio and the near-term launch of our innovative iodine-based supplement, where UPM will be an essential partner in meeting what we believe will eventually be high-volume manufacturing requirements for BioPharmX," continued Krammer.
About UPM Pharmaceuticals
UPM Pharmaceuticals, Inc. a wholly owned division of Gregory Pharmaceutical Holdings, Inc., is an independent drug development and contract manufacturer serving the pharmaceutical and biotechnology industries. We provide high-quality drug development services including formulation development, cGMP clinical and commercial manufacturing, analytical methods development and stability testing. UPM's clients enjoy service that is customized and fast with total quality management characteristics of a customer-focused business. Our history includes successful collaborative interactions with small virtual and large billion-dollar companies providing customized product development services and solutions. UPM focuses on drug development for dosages with oral routes of administration, in solid dosage forms such as capsules and tablets, and semi-solid creams and ointments. Our 475,000 square-foot commercial manufacturing facility based in Bristol, Tennessee allows us to serve our clients' needs from early stage development to large-scale commercial production.
http://www.prnewswire.com/news-releases/upm-p...07563.html
BRISTOL, Tenn., Dec. 10, 2014 /PRNewswire/ -- UPM Pharmaceuticals, a division of Gregory Pharmaceutical Holdings, Inc., has reached an agreement with BioPharmX, Inc. (OTCQB: BPMX) to commercially manufacture solid dose iodine supplement tablets for the consumer products sector. The tablets will be manufactured at UPM's 475,000 square-foot manufacturing facility in Bristol, Tennessee, under a commercial supply agreement. Terms of the agreement were not disclosed.
Dr. John M. Gregory, Chairman and CEO of Gregory Pharmaceutical Holdings, Inc., said, "UPM's new large-scale manufacturing facility and capabilities for solid dose processing is an ideal setting for BioPharmX, which has a focus on patented products in fast growing markets."
Anja Krammer, President of BioPharmx, commented, "BioPharmX is impressed with UPM's customer focus and agile responsiveness toward supporting outsourced manufacturing needs, both critical elements to BioPharmX's anticipated growth in the over-the-counter and dietary supplements industry. We are excited about our planned product portfolio and the near-term launch of our innovative iodine-based supplement, where UPM will be an essential partner in meeting what we believe will eventually be high-volume manufacturing requirements for BioPharmX," continued Krammer.
About UPM Pharmaceuticals
UPM Pharmaceuticals, Inc. a wholly owned division of Gregory Pharmaceutical Holdings, Inc., is an independent drug development and contract manufacturer serving the pharmaceutical and biotechnology industries. We provide high-quality drug development services including formulation development, cGMP clinical and commercial manufacturing, analytical methods development and stability testing. UPM's clients enjoy service that is customized and fast with total quality management characteristics of a customer-focused business. Our history includes successful collaborative interactions with small virtual and large billion-dollar companies providing customized product development services and solutions. UPM focuses on drug development for dosages with oral routes of administration, in solid dosage forms such as capsules and tablets, and semi-solid creams and ointments. Our 475,000 square-foot commercial manufacturing facility based in Bristol, Tennessee allows us to serve our clients' needs from early stage development to large-scale commercial production.
http://www.prnewswire.com/news-releases/upm-p...07563.html
(0)
(0)BioPharmX Corporation (BPMX) Stock Research Links
Scroll down for more posts ▼